Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Remke

Showing results (91-100 of 184) with videos related to

Pageof 19
Sort By:
Cancer Research|October 7, 2010
Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastomaChristopher Traenka, Marc Remke, Andrey Korshunov, et al.
BMC Cancer|February 18, 2016
MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-propertiesSebastian Dietl, Stefanie Schwinn, Susanne Dietl, et al.
Cancer Research|November 23, 2021
BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor MicroenvironmentWei Liu, Paweł Stachura, Haifeng C Xu, et al.
Oncotarget|January 11, 2015
A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastomaFengfei Wang, Marc Remke, Kruttika Bhat, et al.
The Journal of Clinical Investigation|April 10, 2008
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomasStefan Pfister, Wibke G Janzarik, Marc Remke, et al.
Journal of Neuro-Oncology|July 10, 2024
A clinically compatible in vitro drug-screening platform identifies therapeutic vulnerabilities in primary cultures of brain metastasesSebastian Jeising, Ann-Christin Nickel, Johanna Trübel, et al.
Cancer Discovery|August 8, 2014
ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agentsSameer Agnihotri, Kelly Burrell, Pawel Buczkowicz, et al.
Molecular Cancer Therapeutics|May 27, 2020
A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in <i>BRAF</i>-Driven Pediatric Low-Grade Glioma CellsDiren Usta, Romain Sigaud, Juliane L Buhl, et al.
Acta Neuropathologica Communications|April 5, 2020
KLF4<sup>K409Q</sup>-mutated meningiomas show enhanced hypoxia signaling and respond to mTORC1 inhibitor treatmentNiklas von Spreckelsen, Natalie Waldt, Rebecca Poetschke, et al.
Cancer Research|June 22, 2016
PINK1 Is a Negative Regulator of Growth and the Warburg Effect in GlioblastomaSameer Agnihotri, Brian Golbourn, Xi Huang, et al.
Pageof 19

Showing results (91-100 of 184) with videos related to

Sort By:
Pageof 19
Cancer Research|October 7, 2010
Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastomaChristopher Traenka, Marc Remke, Andrey Korshunov, et al.
BMC Cancer|February 18, 2016
MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-propertiesSebastian Dietl, Stefanie Schwinn, Susanne Dietl, et al.
Cancer Research|November 23, 2021
BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor MicroenvironmentWei Liu, Paweł Stachura, Haifeng C Xu, et al.
Oncotarget|January 11, 2015
A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastomaFengfei Wang, Marc Remke, Kruttika Bhat, et al.
The Journal of Clinical Investigation|April 10, 2008
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomasStefan Pfister, Wibke G Janzarik, Marc Remke, et al.
Journal of Neuro-Oncology|July 10, 2024
A clinically compatible in vitro drug-screening platform identifies therapeutic vulnerabilities in primary cultures of brain metastasesSebastian Jeising, Ann-Christin Nickel, Johanna Trübel, et al.
Cancer Discovery|August 8, 2014
ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agentsSameer Agnihotri, Kelly Burrell, Pawel Buczkowicz, et al.
Molecular Cancer Therapeutics|May 27, 2020
A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in <i>BRAF</i>-Driven Pediatric Low-Grade Glioma CellsDiren Usta, Romain Sigaud, Juliane L Buhl, et al.
Acta Neuropathologica Communications|April 5, 2020
KLF4<sup>K409Q</sup>-mutated meningiomas show enhanced hypoxia signaling and respond to mTORC1 inhibitor treatmentNiklas von Spreckelsen, Natalie Waldt, Rebecca Poetschke, et al.
Cancer Research|June 22, 2016
PINK1 Is a Negative Regulator of Growth and the Warburg Effect in GlioblastomaSameer Agnihotri, Brian Golbourn, Xi Huang, et al.
Pageof 19